Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the cooperative systematic studies of the rheumatic diseases program randomized clinical trial of methotrexate, auranofin, or a combination of the two.
Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the cooperative systematic studies of the rheumatic diseases program randomized clinical trial of methotrexate, auranofin, or a combination of the two.
复制标题
对参加风湿性疾病计划随机临床试验(甲氨蝶呤、金诺芬或两者组合)的合作系统研究的类风湿性关节炎患者的疾病进展进行放射学评估。
DOI:
10.1002/art.1780361006
复制
发表时间:
1993
影响因子:
--
通讯作者:
Alarcón,GS
中科院分区:
文献类型:
--
作者:
López-Méndez,A;Daniel,WW;Reading,JC;Ward,JR;Alarcón,GS
Objective.To determine the radiographic progression of disease in rheumatoid arthritis (RA) patients from the Cooperative Systematic Studies of the Rheumatic Diseases clinical trial of auranofin (AUR) versus methotrexate (MTX) versus a combination of the two.Methods.Baseline (week‐0) and study‐end (week‐48) hand/wrist radiographs in 200 of the 211 patients who completed this multicenter trial (95%) were scored blindly by 2 readers for the presence of erosions and joint space narrowing (JSN). Both intraobserver reliability and interobserver reliability were 0.80 for erosions (P≤ 0.001); intraobserver reliability and interobserver reliability were both 0.75 for JSN (P≤ 0.001).Results.Worsening erosion and JSN scores occurred in all 3 treatment groups, but the difference from baseline reached significance only in the AUR group.Conclusion.Clinical improvement has been clearly documented in all 3 treatment groups in this trial. Radiographic deterioration occurs in RA even when clinical features improve, but progression of disease as determined radiographically may be slowed by treatment with MTX.